{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T07:35:10Z","timestamp":1771572910596,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T00:00:00Z","timestamp":1653868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T00:00:00Z","timestamp":1653868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Beta adrenergic receptors (\u03b2-AR) play a key role in regulating several hallmark pathways of both benign and malignant human and canine tumors. There is scarce information on the expression of \u03b2-AR in canine vascular tumors. Therefore, the purpose of the present research work was to study the mRNA expression levels of the three subtypes of the \u03b2-AR genes (<jats:italic>ADRB1, ADRB2, ADRB3<\/jats:italic>) in hemangiosarcoma (HSA) and hemangioma (HA), as well as in vascular hamartomas (VH) from dogs.<\/jats:p><jats:p>Fifty samples (<jats:italic>n<\/jats:italic>\u2009=\u200950) were obtained from 38 dogs. Twenty-three animals had HSA, eight animals HA and seven animals VH. HSA were auricular (<jats:italic>n<\/jats:italic>\u2009=\u20098), splenic (<jats:italic>n<\/jats:italic>\u2009=\u20095), cutaneous (<jats:italic>n<\/jats:italic>\u2009=\u20096), auricular and splenic (<jats:italic>n<\/jats:italic>\u2009=\u20092), cutaneous-muscular (<jats:italic>n<\/jats:italic>\u2009=\u20091) and disseminated (<jats:italic>n<\/jats:italic>\u2009=\u20091). There were seven cases of HSA that were divided into primary tumor and secondary (metastatic) tumor. Skin and muscle samples with a normal histological study were used as control group. <jats:italic>ADRB<\/jats:italic> gene expression was determinate in all samples by real-time quantitative PCR. Results showed that <jats:italic>ADRB1, ADRB2<\/jats:italic> and <jats:italic>ADRB3<\/jats:italic> were overexpressed in HSA when compared to the control group. <jats:italic>ADRB2<\/jats:italic> was overexpressed in HA when compared to the control group. HSA express higher values of <jats:italic>ADBR1<\/jats:italic> (<jats:italic>p<\/jats:italic>\u2009=\u20090.0178) compared to VH. There was a high inter-individual variability in the expression of the three subtypes of <jats:italic>ADBR<\/jats:italic>. No statistically significant difference in the expression of <jats:italic>ADBR<\/jats:italic> genes were observed between HSA primary when compared to metastatic or in different anatomical locations. In conclusion, canine HSA overexpress the three \u03b2-AR subtypes and canine HA \u03b22-AR. High variability was observed in \u03b2-AR mRNA levels amongst HSA cases.<\/jats:p>","DOI":"10.1186\/s12917-022-03317-1","type":"journal-article","created":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T08:04:31Z","timestamp":1653897871000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Gene expression profiles of beta-adrenergic receptors in canine vascular tumors: a preliminary study"],"prefix":"10.1186","volume":"18","author":[{"given":"Jordi","family":"Clanxet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5525-4049","authenticated-orcid":false,"given":"Mariana","family":"Teles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1526-3201","authenticated-orcid":false,"given":"Javier","family":"Hern\u00e1ndez-Losa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel Ruiz-Echarri","family":"Rueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Benitez-Fust\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1702-9531","authenticated-orcid":false,"given":"Josep","family":"Pastor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,30]]},"reference":[{"issue":"4","key":"3317_CR1","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.tips.2011.02.008","volume":"32","author":"CJ Daly","year":"2011","unstructured":"Daly CJ, Mcgrath JC. Previously unsuspected widespread cellular and tissue distribution of beta-adrenoceptors and its relevance to drug action. Trends Pharmacol Sci. 2011;32(4):219\u201326. https:\/\/doi.org\/10.1016\/j.tips.2011.02.008.","journal-title":"Trends Pharmacol Sci"},{"key":"3317_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/B978-0-12-386525-0.00011-1","volume-title":"Primer on the Autonomic Nervous System","author":"CM Stein","year":"2012","unstructured":"Stein CM. \u201c\u03b2-Adrenergic Receptors.\u201d In: Primer on the Autonomic Nervous System. 3rd ed. Amsterdam: Elsevier; 2012. p. 59\u201361.","edition":"3"},{"issue":"2","key":"3317_CR3","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00432-016-2278-1","volume":"143","author":"M Coelho","year":"2017","unstructured":"Coelho M, Soares-Silva C, Brandao D, Marino F, Cosentino M, Ribeiro L. Beta-adrenergic modulation of cancer cell proliferation: Available evidence and clinical perspectives. J Cancer Res Clin Oncol. 2017;143(2):275\u201391. https:\/\/doi.org\/10.1007\/s00432-016-2278-1.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"3317_CR4","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3390\/vetsci2030270","volume":"2","author":"E Dickerson","year":"2015","unstructured":"Dickerson E, Bryan B. Beta adrenergic signalling: A targetable regulator of angiosarcoma and hemangiosarcoma. Vet Sci. 2015;2(3):270\u201392. https:\/\/doi.org\/10.3390\/vetsci2030270.","journal-title":"Vet Sci"},{"issue":"5","key":"3317_CR5","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1158\/1078-0432.CCR-11-0641","volume":"18","author":"SW Cole","year":"2012","unstructured":"Cole SW, Sood AK. Molecular pathways: beta-adrenergic signalling in cancer. Clin Cancer Res. 2012;18(5):1201\u20136. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0641.","journal-title":"Clin Cancer Res"},{"issue":"7\u20138","key":"3317_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.18632\/oncoscience.357","volume":"4","author":"SL Rains","year":"2017","unstructured":"Rains SL, Amaya CN, Bryan BA. Beta-adrenergic receptors are expressed across diverse cancers. Oncoscience. 2017;4(7\u20138):12\u20135. https:\/\/doi.org\/10.18632\/oncoscience.357.","journal-title":"Oncoscience"},{"issue":"3","key":"3317_CR7","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1159\/000489956","volume":"55","author":"CE Escarcega Gonz\u00e1lez","year":"2018","unstructured":"Escarcega Gonz\u00e1lez CE, Rodr\u00edguez MG, Marichal Cancino BA, Gonz\u00e1lez Hern\u00e1ndez A, Villal\u00f3n C. \u03b2-adrenoceptor blockade for infantile hemangioma therapy: Do \u03b23-adrenoceptors play a role? J Vasc Res. 2018;55(3):159\u201368. https:\/\/doi.org\/10.1159\/000489956.","journal-title":"J Vasc Res"},{"issue":"3\u20134","key":"3317_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.18632\/oncoscience.413","volume":"5","author":"CN Amaya","year":"2018","unstructured":"Amaya CN, Perkins M, Belmont A, Herrera C, Vargas A, Khayou T, et al. Non-selective beta blockers inhibit angiosarcoma cell viability and increase progression free- and overall-survival in patients diagnosed with metastatic angiosarcoma. Oncoscience. 2018;5(3\u20134):109\u201319. https:\/\/doi.org\/10.18632\/oncoscience.413.","journal-title":"Oncoscience"},{"key":"3317_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ebiom.2016.02.026","volume":"6","author":"E Pasquier","year":"2016","unstructured":"Pasquier E, Andr\u00e9 N, Street J, Chougule A, Rekhi B, Ghosh J, et al. Effective management of advanced angiosarcoma by the synergistic combination of propranolol and vinblastine-based metronomic chemotherapy: a bench to bedside study. EBioMedicine. 2016;6:87\u201395. https:\/\/doi.org\/10.1016\/j.ebiom.2016.02.026.","journal-title":"EBioMedicine"},{"issue":"3","key":"3317_CR10","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1542\/peds.2008-3458","volume":"124","author":"V Sans","year":"2009","unstructured":"Sans V, de la Roque ED, Berge J, Grenier N, Boralevi F, Mazereeuw-Hautier J, et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics. 2009;124(3):423\u201331. https:\/\/doi.org\/10.1542\/peds.2008-3458.","journal-title":"Pediatrics"},{"issue":"24","key":"3317_CR11","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1056\/NEJMc0708819","volume":"358","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2008","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, de la Dumas RE, Hubiche T. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649\u201352. https:\/\/doi.org\/10.1056\/NEJMc0708819.","journal-title":"N Engl J Med"},{"issue":"11","key":"3317_CR12","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/modpathol.2012.108","volume":"25","author":"KM Chisholm","year":"2012","unstructured":"Chisholm KM, Chang KW, Truong MT, Kwok S, West RB, Heerema-Mckenney AE. \u03b2-Adrenergic receptor expression in vascular tumors. Mod Pathol. 2012;25(11):1446\u201351. https:\/\/doi.org\/10.1038\/modpathol.2012.108.","journal-title":"Mod Pathol"},{"issue":"11","key":"3317_CR13","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1001\/jamadermatol.2015.2554","volume":"151","author":"W Chow","year":"2015","unstructured":"Chow W, Amaya CN, Rains S, Chow M, Dickerson EB, Bryan BA. Growth attenuation of cutaneous angiosarcoma with propranolol-mediated \u03b2-blockade. JAMA Dermatol. 2015;151(11):1226\u20139. https:\/\/doi.org\/10.1001\/jamadermatol.2015.2554.","journal-title":"JAMA Dermatol"},{"key":"3317_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5402\/2011\/416435","volume":"2011","author":"A Chikweto","year":"2011","unstructured":"Chikweto A, McNeil P, Bhaiyat MI, Stone D, Sharma RN. Neoplastic and nonneoplastic cutaneous tumors of dogs in Grenada. West Indies Int Sch Res Not. 2011;2011:1\u20136. https:\/\/doi.org\/10.5402\/2011\/416435.","journal-title":"West Indies Int Sch Res Not"},{"key":"3317_CR15","first-page":"930","volume-title":"Small Animal Clinical Oncology","author":"MT Corbally","year":"2013","unstructured":"Corbally MT. Soft-tissue sarcoma. In: Small Animal Clinical Oncology. 5th ed. Amsterdam: Elsevier; 2013. p. 930\u20134.","edition":"5"},{"key":"3317_CR16","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/9780470752487.ch28","volume-title":"Skin Diseases of the Dog and Cat","author":"TL Gross","year":"2005","unstructured":"Gross TL, Ihrke PJ, Walder EJ, Affolter VK. \u201cVascular tumors.\u201d In: Skin Diseases of the Dog and Cat. 2nd ed. Oxford: Blackwell Science Ltd; 2005. p. 735\u201358.","edition":"2"},{"issue":"125","key":"3317_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1600-0463.2008.125m4.x","volume":"116","author":"H Gamlem","year":"2009","unstructured":"Gamlem H, Nordstoga K, Arnesen K. Canine vascular neoplasia - a population-based clinicopathologic study of 439 tumours and tumour-like lesions in 420 dogs. APMIS. 2009;116(125):41\u201354. https:\/\/doi.org\/10.1111\/j.1600-0463.2008.125m4.x.","journal-title":"APMIS"},{"issue":"6","key":"3317_CR18","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1177\/104063870401600606","volume":"16","author":"PC Schultheiss","year":"2004","unstructured":"Schultheiss PC. A retrospective study of visceral and nonvisceral hemangiosarcoma and hemangiomas in domestic animals. J Vet Diagnostic Investig. 2004;16(6):522\u20136. https:\/\/doi.org\/10.1177\/104063870401600606.","journal-title":"J Vet Diagnostic Investig"},{"key":"3317_CR19","doi-asserted-by":"crossref","unstructured":"Mullin C, Clifford CA. Miscellaneous tumors: hemangiosarcoma. In: Vail DM, Thamm DH, Liptak JM, editors. Withrow & MacEwen\u2019s Small Animal Clinical Oncology. 6th ed.\u00a0St Louis: Elsevier; 2020. p. 773\u20138.","DOI":"10.1016\/B978-0-323-59496-7.00034-7"},{"issue":"4","key":"3317_CR20","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3390\/vetsci2040388","volume":"2","author":"J Kim","year":"2015","unstructured":"Kim J, Graef AJ, Dickerson EB, Modiano JF. Pathobiology of hemangiosarcoma in dogs: research Advances and future perspectives. Vet Sci. 2015;2(4):388\u2013405. https:\/\/doi.org\/10.3390\/vetsci2040388.","journal-title":"Vet Sci"},{"issue":"5","key":"3317_CR21","doi-asserted-by":"publisher","first-page":"347","DOI":"10.4103\/2231-0762.164789","volume":"5","author":"P Shankargouda","year":"2015","unstructured":"Shankargouda P, Roopa SR, Majumdar B. Hamartomas of the oral cavity. J Int Soc Prev Community Dent. 2015;5(5):347\u201353. https:\/\/doi.org\/10.4103\/2231-0762.164789.","journal-title":"J Int Soc Prev Community Dent"},{"issue":"9","key":"3317_CR22","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/j.1751-0813.2009.00472.x","volume":"87","author":"M Gualtieri","year":"2009","unstructured":"Gualtieri M, Cocci A, Monti S, Olivero D. Surgical removal of a localised vascular hepatic hamartoma in a dog. Aust Vet J. 2009;87(9):360\u20132. https:\/\/doi.org\/10.1111\/j.1751-0813.2009.00472.x.","journal-title":"Aust Vet J"},{"issue":"10","key":"3317_CR23","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1292\/jvms.11-0201","volume":"73","author":"M Sakurai","year":"2011","unstructured":"Sakurai M, Morita T, Kondo H, Uemura T, Haruna A, Shimada A. Cerebral vascular hamartoma with thrombosis in a dog. J Vet Med Sci. 2011;73(10):1367\u20139. https:\/\/doi.org\/10.1292\/jvms.11-0201.","journal-title":"J Vet Med Sci"},{"issue":"5","key":"3317_CR24","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1177\/1040638711416852","volume":"23","author":"K Yasuno","year":"2011","unstructured":"Yasuno K, Kobayashi R, Ohmuro T, Kamiie J, Sahara H, Shirota K. Caudal vascular hamartoma accompanied by aberrant arteriovenous structures in a dog. J Vet Diagnostic Investig. 2011;23(5):1051\u20135. https:\/\/doi.org\/10.1177\/1040638711416852.","journal-title":"J Vet Diagnostic Investig"},{"issue":"1","key":"3317_CR25","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1354\/vp.38-1-108","volume":"38","author":"SH Smith","year":"2001","unstructured":"Smith SH, Van Winkle T. Cerebral vascular hamartomas in five dogs. Vet Pathol. 2001;38(1):108\u201312. https:\/\/doi.org\/10.1354\/vp.38-1-108.","journal-title":"Vet Pathol"},{"key":"3317_CR26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1600-0463.2008.125m6.x","volume":"125","author":"L Moe","year":"2008","unstructured":"Moe L, Gamlem H, Dahl K, Glattre E. Canine neoplasia - population-based incidence of vascular tumours. APMIS. 2008;125:63\u20138. https:\/\/doi.org\/10.1111\/j.1600-0463.2008.125m6.x.","journal-title":"APMIS"},{"issue":"3","key":"3317_CR27","doi-asserted-by":"publisher","first-page":"e60021","DOI":"10.1371\/journal.pone.0060021","volume":"8","author":"JM Stiles","year":"2013","unstructured":"Stiles JM, Amaya C, Rains S, Diaz D, Pham R, Battiste J, et al. Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma. PLoS One. 2013;8(3):e60021. https:\/\/doi.org\/10.1371\/journal.pone.0060021.","journal-title":"PLoS One"},{"issue":"2","key":"3317_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2020.614288","volume":"10","author":"J Saha","year":"2021","unstructured":"Saha J, Kim JH, Amaya CN, Witcher C, Khammanivong A, Korpela DM, et al. Propranolol sensitizes vascular sarcoma cells to doxorubicin by altering lysosomal drug sequestration and drug efflux. Front Oncol. 2021;10(2):1\u201315. https:\/\/doi.org\/10.3389\/fonc.2020.614288.","journal-title":"Front Oncol"},{"issue":"6","key":"3317_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12061415","volume":"12","author":"L Filippi","year":"2020","unstructured":"Filippi L, Bruno G, Domazetovic V, Favre C, Calvani M. Current therapies and new targets to fight melanoma: a promising role for the \u03b23-adrenoreceptor. Cancers. 2020;12(6):1\u201316. https:\/\/doi.org\/10.3390\/cancers12061415.","journal-title":"Cancers"},{"issue":"8","key":"3317_CR30","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1056\/nejmoa1404710","volume":"372","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2015","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372(8):735\u201346. https:\/\/doi.org\/10.1056\/nejmoa1404710.","journal-title":"N Engl J Med"},{"issue":"3","key":"3317_CR31","doi-asserted-by":"publisher","first-page":"177","DOI":"10.12788\/j.sder.2016.046","volume":"35","author":"C Trenor","year":"2016","unstructured":"Trenor C. Medical management of vascular anomalies. Semin Cutan Med Surg. 2016;35(3):177\u201381. https:\/\/doi.org\/10.12788\/j.sder.2016.046.","journal-title":"Semin Cutan Med Surg"},{"issue":"1","key":"3317_CR32","doi-asserted-by":"publisher","first-page":"161","DOI":"10.18632\/oncotarget.1083","volume":"5","author":"JK Wolter","year":"2014","unstructured":"Wolter JK, Wolter NE, Blanch A, Partridge T, Cheng L, Morgenstern DA, et al. Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma. Oncotarget. 2014;5(1):161\u201372. https:\/\/doi.org\/10.18632\/oncotarget.1083.","journal-title":"Oncotarget"},{"issue":"7","key":"3317_CR33","doi-asserted-by":"publisher","first-page":"4615","DOI":"10.18632\/oncotarget.2652","volume":"6","author":"M Calvani","year":"2015","unstructured":"Calvani M, Pelon F, Comito G, Taddei ML, Moretti S, Innocenti S, et al. Norepinephrine promotes tumor microenvironment reactivity through \u03b23-adrenoreceptors during melanoma progression. Oncotarget. 2015;6(7):4615\u201332. https:\/\/doi.org\/10.18632\/oncotarget.2652.","journal-title":"Oncotarget"},{"issue":"3\u20134","key":"3317_CR34","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1159\/000163851","volume":"75","author":"MG Perrone","year":"2008","unstructured":"Perrone MG, Notarnicola M, Caruso MG, Tutino V, Scilimati A. Upregulation of \u03b23-adrenergic receptor mRNA in human colon cancer: a preliminary study. Oncology. 2008;75(3\u20134):224\u20139. https:\/\/doi.org\/10.1159\/000163851.","journal-title":"Oncology"},{"issue":"4","key":"3317_CR35","doi-asserted-by":"publisher","first-page":"6446","DOI":"10.18632\/oncotarget.14119","volume":"8","author":"A Montoya","year":"2017","unstructured":"Montoya A, Amaya CN, Belmont A, Diab N, Trevino R, Villanueva G, et al. Use of non-selective \u03b2-blockers is associated with decreased tumor proliferative indices in early stage breast cancer. Oncotarget. 2017;8(4):6446\u201360. https:\/\/doi.org\/10.18632\/oncotarget.14119.","journal-title":"Oncotarget"},{"issue":"3","key":"3317_CR36","doi-asserted-by":"publisher","first-page":"e144893","DOI":"10.1172\/JCI144893","volume":"131","author":"W Li","year":"2021","unstructured":"Li W, Shenkar R, Detter MR, Moore T, Benavides C, Lightle R, et al. Propranolol inhibits cavernous vascular malformations by \u03b21 adrenergic receptor antagonism in animal models. J Clin Invest. 2021;131(3):e144893. https:\/\/doi.org\/10.1172\/JCI144893.","journal-title":"J Clin Invest"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-022-03317-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12917-022-03317-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-022-03317-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T08:06:19Z","timestamp":1653897979000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcvetres.biomedcentral.com\/articles\/10.1186\/s12917-022-03317-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,30]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3317"],"URL":"https:\/\/doi.org\/10.1186\/s12917-022-03317-1","relation":{},"ISSN":["1746-6148"],"issn-type":[{"value":"1746-6148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,30]]},"assertion":[{"value":"23 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During this study no animal experimentation has been done, and only left-over used for other diagnostic purposes has been used. For this, all dogs were sampled with the owner\u2019s permission for clinical or diagnostic reasons, and an owner informed consent was obtained in order to use the left-over in future studies. By doing this we followed the recommended guidelines of the Ethical committee of the Universitat Aut\u00f2noma de Barcelona and Hospital Clinic Veterinary and also we followed relevant guidelines as the Directive 2010\/63\/EU in Europe).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not aplicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"206"}}